Viking Therapeutics Inc (NASDAQ: VKTX) on Friday, plunged -0.58% from the previous trading day, before settling in for the closing price of $31.29. Within the past 52 weeks, VKTX’s price has moved between $18.92 and $81.73.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -23.00%. The company achieved an average annual earnings per share of -86.96%. With a float of $108.96 million, this company’s outstanding shares have now reached $112.29 million.
Let’s determine the extent of company efficiency that accounts for 36 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Viking Therapeutics Inc (VKTX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Viking Therapeutics Inc is 2.98%, while institutional ownership is 69.36%. The most recent insider transaction that took place on Jul 03 ’25, was worth 747,633. In this transaction President & CEO of this company sold 26,889 shares at a rate of $27.80, taking the stock ownership to the 2,388,014 shares. Before that another transaction happened on Jul 03 ’25, when Company’s Chief Financial Officer sold 4,266 for $27.76, making the entire transaction worth $118,428. This insider now owns 168,660 shares in total.
Viking Therapeutics Inc (VKTX) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -86.96% per share during the next fiscal year.
Viking Therapeutics Inc (NASDAQ: VKTX) Trading Performance Indicators
Viking Therapeutics Inc (VKTX) is currently performing well based on its current performance indicators. A quick ratio of 44.25 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.15, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -2.57 in one year’s time.
Technical Analysis of Viking Therapeutics Inc (VKTX)
Looking closely at Viking Therapeutics Inc (NASDAQ: VKTX), its last 5-days average volume was 4.12 million, which is a drop from its year-to-date volume of 4.12 million. As of the previous 9 days, the stock’s Stochastic %D was 89.20%.
During the past 100 days, Viking Therapeutics Inc’s (VKTX) raw stochastic average was set at 69.78%, which indicates a significant decrease from 94.08% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.79 in the past 14 days, which was lower than the 1.87 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $27.72, while its 200-day Moving Average is $38.94. However, in the short run, Viking Therapeutics Inc’s stock first resistance to watch stands at $31.50. Second resistance stands at $31.90. The third major resistance level sits at $32.57. If the price goes on to break the first support level at $30.44, it is likely to go to the next support level at $29.77. Now, if the price goes above the second support level, the third support stands at $29.38.
Viking Therapeutics Inc (NASDAQ: VKTX) Key Stats
Market capitalization of the company is 3.49 billion based on 112,310K outstanding shares. Right now, sales total 0 K and income totals -109,960 K. The company made 0 K in profit during its latest quarter, and -45,630 K in sales during its previous quarter.
